Overcoming Obesity 2023 (Live) -Safety and Efficacy of Tirzepatide for Chronic Weight Management: SURMOUNT-1 and SURMOUNT-2
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMOUNT-1 and SURMOUNT-2.
CME/CE Expiration Date: 11/27/23
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
- Overview of tirzepatide as a novel single molecule GIP and GLP-1 receptor agonists
- Rationale and design of SURMOUNT global trial program for the treatment of obesity and overweight
- Safety and efficacy of tirzepatide for chronic weight management from SURMOUNT-1 and SURMOUNT-2
Ariana M. Chao, PhD, CRNP, FNP-BC
Timothy Garvey, MD, MACE
This session is approved by the American Association of Nurse Practitioners® for 1.0 pharmacology contact hour(s).
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.